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Abstract  
In order to investigate the in vivo dopamine (DA) stimulant properties of selected 3rd generation 
Spice/K2 cannabinoids, BB-22, 5F-PB-22, 5F-AKB-48 and STS-135, their in vitro affinity and 
agonist potency at native rat and mice CB1 receptors was studied. The compounds bind with high 
affinity to CB1 receptors in rat cerebral cortex homogenates and stimulate CB1-induced 
[35S]GTPγS binding with high potency and efficacy. BB-22 and 5F-PB-22 showed the lowest Ki of 
binding to CB1 receptors (0.11 and 0.13 nM), i.e., 30 and 26 times lower respectively than that of 
JWH-018 (3.38 nM), and a potency (EC50, 2.9 and 3.7 nM, respectively) and efficacy (Emax, 217% 
and 203%, respectively) as CB1 agonists higher than JWH-018 (EC50, 20.2 nM; Emax, 163%). 5F-
AKB-48 and STS-135 had higher Ki for CB1 binding, higher EC50 and lower Emax as CB1 
agonists than BB-22 and 5F-PB-22 but still comparatively more favourable than JWH-018.  
The agonist properties of all the compounds were abolished or drastically reduced by the CB1 
antagonist/inverse agonist AM251 (0.1 µM). No activation of G-protein was observed in CB1-KO 
mice.  BB-22 (0.003-0.01 mg/kg i.v.) increased dialysate DA in the accumbens shell but not in the 
core or in the medial prefrontal cortex, with a bell shaped dose-response curve and an effect at 0.01 
mg/kg and a biphasic time-course. Systemic AM251 (1.0 mg/kg i.p.) completely prevented the 
stimulant effect of BB-22 on dialysate DA in the NAc shell. All the other compounds increased 
dialysate DA in the NAc shell at doses consistent with their in vitro affinity for CB1 receptors (5F-
PB-22, 0.01 mg/kg; 5F-AKB-48, 0.1 mg/kg; STS-135, 0.15 mg/kg i.v.). 3rd generation cannabinoids 
can be even more potent and super-high CB1 receptor agonists compared to JWH-018. Future 
research will try to establish if these properties can explain the high toxicity and lethality associated 
with these compounds. 
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Abbreviations 
 
AM 251 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(1-piperidyl)pyrazole-3-carboxamide 
BB-22     1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester 
5F-AKB-48 N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 
5F-PB-22 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester 
DA dopamine 
mPFC  medial Prefrontal Cortex 
NAc Nucleus Accumbens  
NPS new/novel psychoactive substance 
JWH-018 1-pentyl-3-(1-naphthoyl)indole 
STS-135 N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide 
THC delta-9-tetrahydrocannabinol 
 
WIN WIN-55,212-2; (R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-
1,4-benzoxazin-6-yl]-1-napthalenylmethanone 
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1. INTRODUCTION  
Herbal mixtures containing synthetic cannabinoid (SC) receptor agonists and intended to be used as 
a Marijuana surrogate, have been traded in Europe through the Internet under the name of Spice 
since 2004 and in North America, as K2, since 2008 (EMCDDA, 2009). Batches of the same brand 
may possess highly variable SC concentrations (Auwarter et al., 2013; Brents and Prather, 2014; 
Castaneto et al., 2015; Schifano et al., 2015; Schlatter, 2014; Zawilska and Wosjcieszak, 2013). 
Over the last few years, SC have gained popularity and especially so in adolescents and young 
adults. A recent US survey of SC use among students shows a prevalence of 7.4-7.9 % in those 
aged 15/18 years, with Spice products being the second most used drugs after Marijuana (Johnston 
et al., 2013).  
 SC identified in herbal mixtures can be classified into at least 7 categories: 
cyclohexylphenol (cannabicyclohexanol, CCH and CP-47497), classical cannabinoids (HU-210), 
naphthoylindoles (JWH-018 and JWH-073), phenylacetylindoles (JWH-250 and JWH-203), 
benzoylindoles (AM-694 and RCS-4), naphthoylnaphthalenes (CB-13), adamantylindoles (APICA) 
and adamantylindazoles (AKB-48 ‘’APINACA’’and its 5-F derivative). SC intake has been 
associated with the occurrence of florid/acute transient psychosis, relapse/worsening of a pre-
existing psychosis, persisting psychotic disorders/“spiceophrenia”, and manic-like symptoms or 
relapse of pre-existing bipolar disorder (Papanti et al., 2013; Spaderna et al, 2013; van Amsterdam 
et al, 2015). A number of analytically confirmed accidental deaths/suicides have been related to SC 
ingestion, either on their own or in combination with other compounds (Brents and Prather, 2014; 
Papanti et al., 2014; Schifano et al., 2015).  
On the basis of the temporal sequence of their appearance in Spice and K2 samples, three 
generations of SC can be distinguished (ACMD 2009, 2012, 2014). First generation Spice 
cannabinoids, JWH-018, CP 47,497 and HU-210 (ACMD, 2009), are full CB1 receptor agonists 
with affinities that are 4.5, 8.6 and 55 times that of THC respectively. Moreover, in functional tests 
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the above compounds act as full agonists, in contrast to the partial agonist activity of THC 
(Huffman et al., 2005; Atwood et al., 2010, 2011; Marshell et al., 2014).  
.JWH-018 has been recently shown to be self-administered i.v. by rats and mice, to increase 
extracellular dopamine (DA) in the shell of the nucleus accumbens (NAc) and to reduce GABA-A 
receptor inhibition of ventral tegmental area DA neurons in a cannabinoid receptor-dependent 
fashion (De Luca et al., 2015). These properties indicate that JWH-018 demonstrates positive 
reinforcing properties and resembles THC in its DA stimulant properties on DA transmission in the 
NAc (Tanda et al., 1997; Lecca et al., 2006; De Luca et al., 2012).  
In 2009 various European countries and in 2010 various US States regulated the sale and use 
of cannabimimetic ingredients of Spice. This prompted a drastic reduction of the presence of 1st 
generation SC in Spice and K2-like preparations and their substitution with 2nd generation SC 
(ACMD, 2012). These compounds included haloalkyl derivatives of JWH-018, AM-2201 and its 
methyl derivative MAM-2201 and the fluoro alkyl, iodobenzyl derivative AM-694, the n-
methylpiperidinyl AM-2233 and AM-1220, the benzoyl indoles AM-679, RCS-4 and derivatives, 
and adamantoindoles AM-1248 and AB-001. The last (e.g. the 3rd) generation of cannabinoids 
reported in herbal mixtures and in biological samples include compounds with an indazole or 
benzimidazole core replacing the indole (e.g. AKB-48, 5F-AKB-48, FUBIMINA), replacement of 
the carbonyl link of JWH-018 with carboxamide or carboxylate groups (e.g. APICA, SDB005), 
quinolinyl (PB-22 ‘’QUPIC’’, 5F-PB-22, BB-22 ‘’QUCHIC’’) or non-cyclic (ABDICA, AB-
PINACA, 5F-AB-PINACA) secondary structures and novel nitrogenized tails (AB-FUBINACA, 
AB-FUBICA) (Uchiyama et al., 2012; 2013 a,b; ACMD, 2014).   
To date, detailed information on the affinity, agonist potency, intrinsic activity and in vivo 
effects of these 3rd generation cannabinoids is lacking. As part of our continuing interest on the 
mechanism of the reinforcing properties and abuse liability of natural and synthetic cannabinoids, 
we selected four of the 3rd generation cannabinoids found in Spice/K2 products, namely BB-22, 5F-
PB-22, 5F-AKB-48 (also known as 5F-APINACA) and STS-135. In the UK, synthetic 
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cannabinoids are the most frequently represented Novel Psychoactive Substance (NPS) category 
identified in samples submitted for analysis by a range of sources, with 5F-AKB-48 and 5-FPB-22 
(‘clockwork orange’; ‘exodus’; and others) having been reported as the most identified NPS 
molecules overall (Wedinos, 2014). The recent trend of SC fluorination may increase the 
compounds’ lipophilicity, hence enhancing the absorption through biological membranes/blood 
brain barrier (Schifano et al., 2015). The fluorinated SC STS-135 can be identified either on its own 
(‘clockwork orange’ and others) or in combination with other ’spice’ molecules in products such as 
‘Moroccan’ (Wedinos, 2014). Similarly, 5F-PB-22 (‘Psyclone’ and others) is the terminally 
fluorinated analogue of QUPIC (also known as PB-22). Psyclone incense is priced around £10 per 
gram, with users reporting intense and long-lasting euphoria/relaxation/visual hallucinations effects 
(Santacroce et al., 2015). Furthermore, BB-22, identified in products such as ‘Vertex’ and others, 
has recently been associated with a range of hospitalizations in the UK (Plymouth Herald, 2015). In 
this study, the above compounds’ binding and agonist properties on native CB1 receptors in brain 
homogenates from rats and mice have been investigated. In addition, the in vivo effects on DA 
transmission, as monitored by brain microdialysis, of the compound which provided with the 
highest potency and efficacy as an agonist of CB1 receptors, namely BB-22, was studied in detail. 
Thus, the effect of BB-22 on DA transmission in the rat NAc shell and core and medial prefrontal 
cortex (mPFC) was investigated. The in vivo effects of the other three compounds on NAc shell DA 
transmission was also tested.  
2. MATERIALS AND METHODS 
2.1 Animals  
Male Sprague-Dawley rats (Harlan Italy), C57BL/J6 and CB1 knockout  (KO) mice (originally bred 
on C57BL/6J background were kindly donated by Dr Aron H. Lichtman, Department of 
Pharmacology and Toxicology, Virginia, Commonwealth, Virginia) were used for in vitro 
experiments (rats of 200-250g and mice of 17-20 g, respectively) and for in vivo microdialysis (rats 
of 275-300 g). Rats and mice were housed 4 and 10 per cage, respectively, in standard plastic cages 
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with wood chip bedding, at temperature of 22 ± 2 °C and 60% humidity and under a 12 h light/dark 
cycle (lights on from 7.00 a.m.). Tap water and standard laboratory rodent chow (Mucedola, 
Settimo Milanese, Italy) were provided ad libitum in the homecage. All animal experiments were 
carried out in accordance with the Guidelines for the Care and Use of Mammals in Neuroscience 
and Behavioral Research according to Italian (D.L. 116/92 and 152/06) and European Council 
directives (609/86 and 63/2010) and in compliance with the approved animal policies by the Ethical 
Committee for Animal Experiments (CESA, University of Cagliari) and the Italian Ministry of 
Health. We made all efforts to minimize pain and suffering, and to reduce the number of animals 
used. 
2.2 Drugs 
5’-O-(3-[35S]thiotriphospate) ([35S]GTPγS) (1250 Ci/mmol), [3H]CP,55940 (131.8 Ci/mmol) ((-)-
cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol) were 
purchased from Perkin-Elmer Life Sciences, Inc. (Boston, MA, USA). Guanosine 5′- diphosphate 
(GDP), and guanosine 5′-O-(3-thiotriphosphate) (GTPγS) were obtained from Sigma/RBI (St. 
Louis, MO, USA). CP55,940, WIN-55,212-2  (WIN) JWH-018 and AM 251 were purchased from 
Tocris (Bristol, UK). 5F-AKB-48, 5F-PB-22, BB-22, and STS-135 were purchased from an Internet 
source (www.researchchemist.co.uk).  
For biochemical experiments, drugs were dissolved in dimethyl sulfoxide (DMSO). The DMSO 
concentration used in the different assays never exceeded 0.1% (v/v) and had no effects on [3H]CP-
55,940 binding and [35S]GTPγS binding assay. For in vivo microdialysis, drugs were solubilized in 
2% EtOH, 2% Tween 80 and 96 % saline and administered intravenously (i.v.; 1 ml/kg) at different 
doses depending on the group of animals. BB-22: 0.003-0.1 mg/kg; 5F-PB-22: 0.01 mg/kg; 5F-
AKB-48 0.1 mg/kg; STS-135 0.15 mg/kg. AM-251 was administered intraperitoneally (i.p.; 3 
ml/kg) at the dose of 1 mg/kg. 
2.3 Chemical Characterization of Cannabinoids Sourced from the Internet 
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To confirm their identity and purity, the substances were evaluated using gas chromatography mass 
spectrometry with electron ionisation (GC-EI-MS), 400 MHz nuclear magnetic resonance 
spectroscopy (NMR), and high performance liquid chromatography (HPLC). Reference standards 
of the four cannabinoids were purchased from Chiron (Norway) for comparison. GC-EI-MS was 
used for the initial identification where the fragmentation pattern of all four Internet products 
correlated to the cannabinoid claimed on the label, when compared to that of the reference standard 
as well as the SWG Drug library (Version 2.1). The identification was further confirmed using 
NMR where the number of peaks and splitting patterns were consistent with the cannabinoid 
chemical structures and in line with spectra produced by SWG Drug. HPLC was then used to 
evaluate the purity of the cannabinoid products where the purity of 5F-AKB-48, 5F-PB-22, BB-22, 
and STS-135 were determined to be 93 ± 1%, 95.2 ± 0.8%, 90.6 ± 0.6%, and 91 ± 2%, respectively. 
Full methods and data interpretation are available in the Supplementary Information. 
2.4 In Vitro Experiments 
2.4.1 [3H]CP-55,940 Binding Assay. Rats were sacrificed by decapitation. Brains were collected 
and cerebral cortices were rapidly dissected and placed on an ice-cold plate. After thawing, tissues 
were homogenated in 20 volumes (w/v) of ice-cold TME buffer (50 mM Tris-HCl, 1 mM EDTA, 
and 3 mM MgCl2, pH 7.4). The homogenates were centrifuged at 1000g for 10 min at 4 °C, and the 
resulting supernatants were centrifuged at 45000g for 30 min at 4 °C. Aliquots of membranes were 
frozen at -80 °C until the day of experiment. The Bradford protein assay was used for protein 
determination using bovine serum albumin (BSA) as a standard in accordance with the supplier 
protocol (Bio-Rad, Milan, Italy). [3H]CP-55,940 binding was carried out as previously described 
(Manera et al., 2006). Briefly, the membranes (40-50 µg of protein) were incubated for 1 h at 30 °C 
with [3H]CP-55,940 (0.5 nM) in a final volume of 0.5 mL of TME buffer containing 5 mg/mL 
BSA. Nonspecific binding was determined in the presence of 10 µM CP-55,940. Incubation was 
terminated by rapid filtration through Whatman GF/C filters pretreated with 0.5% (w/v) 
polyethyleneimine (PEI), using a Brandell 30-sample harvester (Gaithersburg, MD). Filters were 
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washed three times with ice-cold Tris-HCl buffer (pH 7.4) containing 1 mg/ml BSA. Filter-bound 
radioactivity was counted in a liquid scintillation counter (Packard Tricarb 2810 TR, Packard, 
Meridien, CT), using 3 mL of scintillation fluid (Ultima Gold Packard, MV, Meridien, CT). 
[3H]CP-55,940 displacement curves were plotted using serial dilutions ranging from 10-11 to 10-5 M 
unlabeled compounds and [3H]CP-55,940 (0.5 nM). Independent experiments were repeated on 
membrane preparations from at least three different experiments. The calculation of the IC50 (the 
concentration that inhibits 50% of specific radioligand binding) was performed by nonlinear curve 
fitting of the concentration-effect curves using GraphPad Prism, San Diego, CA. The F-test was 
used to determine the best approximation of a nonlinear curve fit to a one- or two- site model (P < 
0.05). IC50 values were converted to Ki values by means of the Cheng and Prusoff equation (Cheng 
and Prussoff, 1973). 
2.4.2 [35S]GTPγS Binding Assay. Rat and mouse cortical membranes were suspended in 20 
volumes of cold centrifugation buffer (50 mM Tris-HCl, 3 mM MgCl2, 1 mM EDTA, pH 7.4) and 
homogenized using a homogenizer system (Glass-Col, Terre Haute, IN). The homogenate was 
centrifuged at 48000g for 10 min at 4 °C. The pellet was then resuspended in the same buffer, 
homogenized, and centrifuged as previously described. The final pellet was subsequently 
resuspended in assay buffer (50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA, 100 mM NaCl, pH 
7.4), homogenized, and diluted to a concentration of ∼2 mg/mL with assay buffer. Membrane 
aliquots were then stored at -80 °C until use. [35S]GTPγS binding was measured as previously 
described (Manera et al., 2006). Briefly, mouse and rat brain membranes (5-10 µg of protein) were 
incubated with compounds at 30 °C in assay buffer containing 0.1% BSA in the presence of 0.05 
nM [35S]GTPγS and 30 µM GDP in a final volume of 1 ml. After 60 min incubation, samples were 
filtered using a Packard Unifilter-GF/B, washed twice with 1 ml of ice-cold 50 mM Tris-HCl, pH 
7.4 buffer, and dried for 1 h at 30 °C. The radioactivity on the filters was counted in a liquid 
microplate scintillation counter (TopCount NXT, Packard, Meridien, CT) using 30 µl of 
scintillation fluid (Microscint 20, Packard, Meridien, CT). Concentration-effect curves were 
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determined by incubating membranes with various concentrations of compounds (0.1 nM-10 µM) 
in the presence of 0.05 nM [35S]GTPγS and 30 µM GDP. Nonspecific binding was measured in the 
presence of 10 µM unlabeled GTPγS. Basal binding was assayed in the absence of agonist and in 
the presence of GDP. Stimulation by the agonist was defined as a percentage increase above basal 
levels (i.e., {[dpm(agonist) - dpm(no agonist)]/dpm(no agonist)} × 100). Nonlinear regression 
analysis of concentration-response data was performed using Prism 6.0 software (GraphPad Prism 
program, San Diego, CA) to calculate Emax (maximal stimulation over basal levels) and EC50 
(concentration of agonist to obtain 50% of the maximal effect) values.  
2.5 In vivo microdialysis 
2.5.1 Surgery. Male Sprague-Dawley rats (275-300 g; Harlan, Italy) were anaesthetised with 
Equitesin (3ml/kg ip; chloral hydrate 2.1 g, sodium pentobarbital 0.46 g, MgSO4 1.06 g, propylene 
glycol 21.4 ml, ethanol (90%) 5.7 ml, H2O 3 ml) placed in a stereotaxic apparatus and implanted 
with vertical dialysis probes (1.5 or 3 mm dialyzing portion for NAc or mPFC, respectively) in the 
NAc shell (A+2.2, L+1.0 from bregma, V-7.8 from dura) or core (A+1.4; L+1.6 from bregma; V-
7.6 from dura) or in the mPFC (A+3.7, L+0.8 from bregma, V-5.0 from dura), according to the rat 
brain atlas of Paxinos and Watson (1998). In order to perform intravenous (i.v.) drug 
administration, a catheter (Silastic, Dow Corning Corporation, Michigan, USA) was inserted in the 
right jugular vein as previously described (De Luca et al., 2014). 
2.5.2 Analytical Procedure. On the day following surgery, probes were perfused with Ringer's 
solution (147 mM NaCl, 4 mM KCl, 2.2 mM CaCl2) at a constant rate of 1 µl/min. Dialysate 
samples (10  µl) were injected into an HPLC equipped with a reverse phase column (C8 3.5 um, 
Waters, USA) and a coulometric detector (ESA, Coulochem II) to quantify DA. The first electrode 
of the detector was set at +130 mV (oxidation) and the second at -175 mV (reduction). The 
composition of the mobile phase was: 50 mM NaH2PO4, 0.1 mM Na2-EDTA, 0.5 mM n-octyl 
sodium sulfate, 15% (v/v) methanol, pH 5.5. The sensitivity of the assay for DA was 5 fmol/sample. 
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2.5.3 Histology. At the end of the experiment, animals were sacrificed and their brains removed and 
stored in formalin (8%) for histological examination to verify the correct placement of the 
microdialysis probe. 
2.6 Statistical Analysis  
All the numerical data are given as mean ± SEM. Data were analyzed by utilizing one-way 
ANOVA or repeated measures ANOVA or T-test. Results from treatments showing significant 
overall changes were subjected to Tukey’s tests or Dunnett’s tests for post hoc comparisons, with 
significance for p < 0.05.  
3. RESULTS 
3.1 IN VITRO STUDIES 
3.1.1 Agonist-stimulated [35S]GTPγS binding 
As shown in Fig. 2 A-B, at 1 µM concentration WIN and JWH-018, our reference compounds, 
stimulated [35S]GTPγS binding to rat cortex membranes to approximately 150% and 170%, 
respectively, of the basal activity. BB-22, 5F-PB-22, 5F-AKB-48, and STS-135 produced greater 
G-protein stimulation than the full CB1 receptor agonist, WIN. Specifically, the stimulation of 
GTPγS induced by 1 µM of BB-22 and 5F-PB-22 was significantly (p<0.01) greater than the 
amount of stimulation produced by WIN (Fig. 1A). WIN and all compounds produced no GTPγS 
stimulation when co-incubated with AM 251 (0.1 µM), a CB1 receptor antagonist/inverse agonist 
(Fig. 2 A-B), suggesting that all four test compounds activate a G protein coupled to the CB1 
receptor.  
 [35S]GTPγS binding was stimulated in a concentration-dependent and saturable manner by the 
prototypic indole-derived synthetic cannabinoid JWH-018 and by all four synthetic cannabinoids 
5F-AKB-48, STS-135, BB-22 and 5F-PB-22 (Fig. 3, Table 1). All compounds possess nanomolar 
potency at CB1 receptors, with BB-22 and 5F-PB-22 being approximately 5-7 fold more potent 
than JWH-018. EC50 values for BB-22 and 5F-PB-22 were significantly lower than EC50 value for 
JWH-018 (ANOVA: F(4,14) = 14.78, P< 0.0001, p<0.05, Dunnett’s test), while no difference was 
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recorded in the EC50 value for STS-135 and 5F-AKB-48 (ANOVA: F (4,14) = 14.78 P< 0.001). 
These latter compounds display similar potency to JWH-018 for stimulating GTPγS binding-CB1 
mediated (Table 1). The maximal efficacy (Emax) of G-protein activation by JWH-018 and STS-
135 was similar while the other compounds (5F-AKB-48, BB-22 and 5F-PB-22) exhibited 
significant enhanced efficacy compared to JWH-018 (ANOVA F (4,14) = 11.56 P< 0.001). The rank 
order of potency and efficacy was BB-22 = 5FP-22 > JWH-018 = 5F-AKB-48= STS-135 and BB-
22 = 5FP-22 > 5F-AKB-48> STS-135 = JWH-018, respectively (Table 1). Lastly, to confirm the 
involvement of the cannabinoid CB1 receptor in the activation of G protein we performed 
concentration-effect curves of our compounds in mouse cortex membrane homogenates of CB1-KO 
and wild-type mice. As shown in Fig. 4, all compounds stimulated [35S]GTPγS binding in a 
concentration-dependent manner in cortex of wild-type mice with EC50 and Emax values of 38 ± 
5.7 nM and 158 ± 2.4 %, 28 ± 3.2 nM and 167 ± 3.7 %, 15 ± 1.7 nM and 159 ± 1.5 %,  4 ± 0.9 nM 
and 183 ± 5.5 %,  1.46 ± 0.14 nM and 187 ± 3.6 %, for JWH-018, 5F-AKB-48, STS-135, 5F-PB-22 
and BB-22, respectively. Importantly, no activation of G protein was observed in CB1-KO mice.   
3.1.2 Effects of JWH-018, 5F-AKB48, STS-135, BB-22 and 5F-PB-22 on cannabinoid CB1 
receptor binding 
To determine the affinity of JWH-018 and the other compounds to the CB1 receptor, we used a 
radiolabelled competition binding assay in rat cortical membranes. Indeed, high levels of CB1 
receptors are expressed in the central nervous system, while only negligible CB2 receptors 
quantities are present (Pertwee, 2005). In good agreement with previous published data  (Devane et 
al., 1988; Thomas et al., 1998), the Kd and Bmax obtained by Scatchard analysis of [3H]CP55,940 
saturation binding were 2.08 ± 0.16 picomol/mg protein and 0.33 ± 0.06 nM, respectively (n=3, 
data not shown). As expected, JWH-018 in rat cortical membranes caused complete inhibition of 
the specific binding of [3H]CP55,940 with a Ki of 3.4 ± 0.6 nM (Fig. 4). As shown in Table 1, all 
four test compounds displaced [3H]CP55,940 binding with varying affinities ranging from 0.11 ± 
0.03 for BB-22 to 1.9 ± 0.18 for STS-135. Indeed, Ki values of these compounds were significantly 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
13 
 
lower compared to our reference compound JWH-018, with the rank order of CB1 receptor affinity 
BB-22 = 5FPB-22 > 5F-AKB-48 > STS-135 > JWH-018 (Table 1). 
3.2 IN VIVO MICRODIALYSIS STUDIES 
Rat basal values of DA, expressed as fmoles/10 µl sample (mean ± SEM), were: NAc shell 52 ± 5 
(N =50), NAc core 55 ± 4 (N =25), mPFC 16± 2 (N =21).  
3.2.1 Effect of BB-22 administration on DA transmission in the NAc shell and core, and in the 
mPFC 
In this first experiment, we studied the effect of four doses of BB-22 (0.003, 0.01, 0.03, 0.1, mg/kg 
i.v.) on extracellular DA levels in NAc shell and core, and mPFC. As shown in Fig. 6, the dose-
response curve of the effect of BB-22 on dialysate DA is bell-shaped with the dose of 0.01 mg/kg 
increasing DA levels preferentially in the NAc shell as compared to the NAc core and mPFC. No 
significant effects were observed in the NAc core and mPFC. Three-way ANOVA showed a main 
effect of dose [F(3,75)=4.46; p < 0.01], brain area [F(2,75)=7.72; p <0.001] and time [F(12,900)=4.24; p < 
0.001], and a significant dose x brain area interaction [F(6,75)=6.46; p < 0.0001]. Tukey post hoc 
tests showed an increase of dialysate DA in the NAc shell after 0.01 mg/kg of BB-22 revealing 
differences at the 20-40 and 90-120 min sample with respect to basal value, to vehicle treated 
animals implanted in NAc shell, and to the same dose (0.01 mg/kg) treated animals implanted in the 
NAc core (90 min sample) and in the mPFC (30, 90 min sample). 
3.2.2 Role of CB1 receptors on the NAc shell DA stimulation induced by BB-22  
In this experiment, we studied the effect of CB1 receptor blockade by the inverse 
agonists/antagonists AM 251 on the NAc shell DA response to BB-22 (0.01 mg/kg i.v.) in rats (Fig. 
7). In AM 251 pre-treated animals, two-way ANOVA showed a main effect of treatment 
[F(1,11)=12.07; p< 0.005], and treatment x time interaction [F(18,198)=2.2; p < 0.005]. Tukey’s post 
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hoc tests revealed that pre-treatment with AM-251 significantly reduced dialysate DA in the NAc 
shell as compared to rats pre-treated with vehicle (90, 140,150,180 min sample). 
3.2.3 Effect of 5F-PB-22, 5F-AKB-48, and STS-135 administration on DA transmission in the 
NAc shell  
In this set of experiments, we studied the effect of 5F-PB-22, 5F-AKB-48, and STS-135 on 
extracellular DA levels in the NAc shell. As shown in Fig. 8, all the drugs tested stimulated DA 
transmission in the NAc shell.  A two-way ANOVA showed the following main effects: 5F-PB-22 
treatment [F(1,10)=15.97; p< 0.005]; 5F-AKB-48 treatment [F(1,11)=63.39; p< 0.001], 5F-AKB-48 
time x treatment [F(18,198)=1.7; p< 0.05]; STS-135 time [F(18,144)=2.16; p< 0.05], STS-135 time x 
treatment [F(18,144)=2.1; p< 0.005]. Tukey post hoc tests showed a larger increase of dialysate DA in 
the NAc shell after all the cannabinoids tested revealing differences at the 30 and 40 min samples 
with respect to basal value (5F-PB-22); at the 60, 100 and 150 min samples with respect to basal 
value and at the 60 and 100 min samples compared to vehicle (5F-AKB-48); at the 60 min sample 
with respect to basal value and to vehicle (STS-135). 
4. DISCUSSION 
The main findings of this study are that the four 3rd generation cannabinoids, BB-22, 5F-PB-22, 5F-
AKB-48 and STS-135 are high affinity ligands and potent full agonists at the native rat and mice 
brain CB1 receptors and stimulate in vivo DA transmission in the NAc shell at doses consistent with 
their in vitro CB1 receptor affinity. Our in vitro findings demonstrate that BB-22, 5F-PB-22, 5F-
AKB-48 and STS-135 bind with nanomolar affinity to CB1 receptors in rat cerebral cortex 
homogenates and stimulate CB1-induced [35S]GTPγS binding with high potency and efficacy. 
Previous research has shown that JWH-018, our reference compound, binds with and activates CB1 
receptors with high affinity and potency and displays in vivo cannabimimetic activity, i.e., 
antinociception, hypothermia, catalepsy and locomotor suppression (Brents et al., 2011; Wiley et 
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al., 2012; Vigolo et al., 2015). The G protein activation induced by JWH-018 and by all compounds 
was completely suppressed by the CB1 antagonist/inverse agonist AM 251 and totally absent in 
CB1-KO mice. Taken together these data indicate that BB-22, 5F-PB-22, 5F-AKB-48 and STS-135 
activate a G-protein coupled CB1 receptor. The rank order of potency and efficacy as CB1 receptor 
agonists correlated with CB1 receptor binding affinity, and all four compounds were full agonists in 
[35S]GTPγS binding studies as compared to JWH-018. Notably, the most potent compounds, the 
fluorinate 5F-PB-22 and BB-22, possess greater CB1 receptor agonist potency (5 and 7 fold, 
respectively) and efficacy and a higher binding affinity (26 and 30 fold, respectively) at CB1 
receptors compared to JWH-018. Among the 4 SC, BB-22, the compound provided with the highest 
affinity for CB1 receptors and the highest intrinsic activity as a CB1 receptor agonist, was selected 
to be tested for its in vivo effects on DA transmission, as estimated by DA microdialysis. We 
examined BB-22 in three terminal DA areas, namely the NAc shell and core and the medial PFC. 
Using a range of 4 doses (0.003-0.1 mg/kg i.v.), BB-22 increased dialysate DA in the NAc shell at 
the intermediate dose of 0.01 mg/kg i.v. Most importantly, this effect was prevented by AM 251 at 
a dose that did not affect basal dialysate DA.  The dose of BB-22 that increased dialysate DA in the 
NAc shell is about 10 times lower than the dose of JWH-018 that elicits a quantitatively similar 
peak increase of dialysate DA in the NAc shell (about 50% over basal) and compares favourably 
with the difference in Ki between the two compounds as ligands of native rat CB1 receptors (BB-
22, 0.11 nM; JWH-018, 3.38 nM). BB-22 also shares with JWH-018 the bell shaped dose-response 
curve of the increase in NAc shell DA, with loss of the effect at the highest dose tested. 
Interestingly, the stimulation of dialysate DA in the NAc shell took place within a rather narrow 
range of doses, a feature that differentiates these compounds from THC as well as from 
psychostimulants, nicotine and narcotic drugs of abuse (Di Chiara et al, 2004; Pontieri et al., 1995 
and 1996; Tanda et al., 1997). The other three compounds were tested for their effects on dialysate 
DA in the NAc shell at a single dose level, selected on the basis of the ratio between the Ki of 
JWH-018 and BB-22 for CB1 receptors and the doses of the same compounds that activate in vivo 
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NAc shell DA transmission. Thus, doses of 0.01 mg/kg i.v. of 5F-PB-22, 0.1 mg/kg of 5F-AKB-48 
and 0.15 mg/kg of STS-135 were tested. At these doses, all compounds increased dialysate DA in 
the NAc shell to a similar extent to BB-22 (max < 50% over basal). In the case of 5F-AKB-48 the 
increase of dialysate DA was delayed. In the case of BB-22 the biphasic time-course of dialysate 
DA in the NAc shell could be due to the formation of active metabolites while the delayed effect of 
5F-AKB-48 might be due to slow passage through the blood-brain-barrier due to steric hindrance 
related to the bulky adamantyl residue.  
In conclusion, we have shown that four representatives of 3rd generation Spice/K2 
cannabinoids are highly potent and effective agonists of CB1 receptors and, consistent with the 
properties of THC and synthetic cannabinoids agonists like WIN 55,2012-2 (Lecca et al., 2006) and 
JWH-018 (De Luca et al., 2015), activate DA transmission selectively in the rat NAc shell. In the 
absence of direct evidence for reinforcing properties as deduced from i.v. self-administration 
studies, the property of activating DA transmission in the NAc shell provides circumstantial pre-
clinical evidence for a putative abuse liability of these compounds. The present findings are a 
reason for further clinical concern. Users do not seem to be aware of the serious adverse effects 
related to SC misuse, since these compounds may be perceived to be somehow equivalent to 
Marijuana and hence “safe” and “natural” (Santacroce et al., 2015; Schifano et al., 2015). 
Appropriate, non-judgemental, prevention campaigns with a special focus on the differences 
between SC and cannabis may need to be organized on a large scale. At the same time, clinicians 
need to be regularly updated about NPS, including SC, to promptly recognize signs/symptoms of 
intoxication (Simonato et al., 2013; Papanti et al., 2014; Schifano et al., 2015). 
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Figure legends 
Figure 1 
Structures of selected synthetic cannabinoids. 
 
Figure 2 
Effect of WIN, JWH-018 and its derivatives on [35S]GTPγS binding in rat cortical 
membranes.  
WIN, JWH-018, BB-22, 5F-PB-22 (2A), 5F-AKB-48 and STS-135 (2B) were tested alone or in 
combination with the CB1 receptor antagonist/inverse agonist, AM 251 (0.1 µM). Data, expressed 
as percentage of basal values, are means ± SEM of at least three determinations in triplicate. The 
horizontal dotted line indicates baseline values. One-way ANOVA: 2A, F(9,39) =42,45 P<0.0001; 
2B: F(9,39) = 37,30 P< 0.0001 **p< 0.01 vs WIN ,  Tukey’ test.  
Figure 3 
Concentration-response curves of compound-stimulated [35S]GTPγS binding in rat cortical 
membranes.   
Data are expressed as mean percentage of basal values of GTPγS binding ± SEM of at least four 
independent experiments. Rat cortical membranes were incubated with various concentrations of 
BB-22 (black squares), 5F-PB-22 (red triangles), 5F-AKB-48 (green triangles), STS-135 (magenta 
diamonds), and JWH-018 (blue circles), as described in Material and Methods. The parameters 
describing the different curves are given in Table 1. 
Figure 4 
Concentration-response curves of compounds-stimulated [35S]GTPγS binding in mouse 
cortical membranes of CB1-KO and wild-type mice. 
Data represent a typical experiment out of three independent experiments. EC50, of Wild-Type mice: 
BB-22 (black squares), 1.7 nM; 5F-PB-22 (red triangles), 3.4 nM; 5F-AKB-48 (green triangles), 
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28 nM; STS-135 (magenta diamonds), 15 nM; JWH-018 (blue circles): 36 nM. All compounds fail 
to activate GTPgS binding in CB1-KO mice (dotted lines). 
Figure 5 
Displacement curves of [3H]CP55,940 in rat cortical membranes by BB-22, 5F-PB-22, 5F-
AKB-48, STS-135, and JWH-018.  
Data are expressed as means ± SEM of at least four independent experiments, each performed in 
triplicate. The calculation of IC50 was performed by non-linear curve fitting of the concentration-
effect curves using GraphPad Prism. The F-test was used to determine the best approximation of a 
non-linear curve fit to one or two site models (p < 0.005). IC50 values were converted to Ki values 
by means of the Cheng and Prusoff equation (Cheng and Pursoff, 1973).  
Figure 6 
Effect of BB-22 administration on DA transmission in the NAc shell, NAc core, and mPFC.  
Results are expressed as mean ± SEM of change in DA extracellular levels expressed as the 
percentage of basal values. The arrow indicates the start of BB-22 i.v. injection at the dose of 0.003 
mg/kg (magenta triangles), 0.01 mg/kg (red triangles), 0.03 mg/kg (green squares), 0.1 mg/kg 
(blue diamonds), or vehicle (black circles) in the NAc shell (A), NAc core (B), and mPFC (C). 
Solid symbol: p < 0.05 with respect to basal values; *p < 0.05 vs veh NAc shell group; 
 
× p < 0.01 
vs 0.01 NAc core group; § p < 0.01 vs 0.01 mPFC group; (NAc shell N= 29; NAc core N= 27; 
mPFC N= 21) (Three-way ANOVA, Tukey’s post hoc). 
Figure 7 
Blockade of BB-22 effect on increase of DA transmission in the NAc shell by AM 251.  
 Results are expressed as mean ± SEM of change in DA extracellular levels expressed as the 
percentage of basal values. The arrow indicates the start of BB-22 i.v. injection at the dose of 0.01 
mg/kg in rats pre-treated with AM 251 (1.0 mg/kg i.p., 30 min before agonist) (circles) or vehicle 
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(triangles). Solid symbol: p < 0.05 with respect to basal values; *p < 0.05 vs veh group. (NAc shell 
veh N=6; NAc shell AM N=3) (Two-way ANOVA, Tukey’s post hoc).  
Figure 8 
Effect of 5F-PB-22, 5F-AKB-48, STS-135 administration on DA transmission in the NAc shell.  
Results are expressed as mean ± SEM of change in DA extracellular levels expressed as the 
percentage of basal values. The arrow indicates the start of cannabinoid i.v. injection: (A) 5F-PB-22 
0.01 mg/kg (triangles), (B) 5F-AKB-48 0.1 mg/kg (diamonds), and (C) STS-135 0.15 mg/kg 
(squares), or vehicle (circles) in the NAc shell. Solid symbol: p < 0.05 with respect to basal values; 
*p < 0.05 vs Veh group (5F-PB-22, N= 6; 5F-AKB-48 N= 7 ; STS-135  N= 5; Veh N=17) (Three-
way ANOVA, Tukey’s post hoc). 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
20 
 
Financial disclosure  
The authors declare that the research was conducted in the absence of any commercial or financial 
relationships that could be construed as a potential conflict of interest. 
Acknowledgements 
This research has been funded by the European Commission (Drug Prevention and Information 
Programme 2014-16, contract no. JUST/2013/DPIP/AG/4823, EU-MADNESS project), and by the 
Fondazione Banco di Sardegna (Prot. U404.2015/AI.338.MGB Prat.2015.0713). The authors would 
like to thank Dr. Pierluigi Caboni and Dr. Graziella Tocco for the help with the chemical 
characterization of cannabinoids by GC/MS and NMR analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
21 
 
References 
Advisory Council on the Misuse of Drugs (ACMD), 2009, Consideration of the Major Cannabinoid 
Agonists. Home Office, London. 
 
Advisory Council on the Misuse of Drugs (ACMD), 2012, Further Consideration of Synthetic 
Cannabinoids, Home Office, London 
 
Advisory Council on the Misuse of Drugs (ACMD), 2014, ‘’Third generation’’ synthetic 
cannabinoids, Home Office, London 
 
Atwood, B.K., Huffman, J., Straiker, A., Mackie, K., 2010. JWH018, a common constituent of 
‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB(1) receptor agonist. Br. J. 
Pharmacol. 160: 585–593. 
 
Atwood, B.K., Lee, D., Straiker, A., Widlanski, T.S., Mackie, K., 2011. CP 47,497-C8 and 
JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1)cannabinoid 
receptor agonists. Eur J Pharmacol. 659: 139-45.  
 
Auwarter, V., Dargan, P.I., Wood, D.M., 2013. Synthetic Cannabinoid Receptor Agonists. Chapter 
in: Novel Psychoactive Substances. Edited by: Paul I. Dargan and David M. Wood. Elsevier. 
 
Brents, L.K., Reichard, E.E., Zimmerman, S.M., Moran, J.H., Fantegrossi, W.E., Prather, P.L., 
2011. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro 
and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 6, e21917  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
22 
 
Brents, L.K., Prather, P.L., 2014. The K2/Spice phenomenon: emergence, identification, legislation 
and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab 
Rev. Feb; 46(1): 72-85.  
 
Castaneto, M.S., Wohlfarth, A., Desrosiers, N.A., Hartman, R.L., Gorelick, D.A., Huestis, M.A., 
2015. Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug 
Metab Rev. 2015 May;47(2):124-74.  
 
Cheng, Y.,C., Prusoff, W.H., 1973, Relationship between the inhibition constant (Ki) and the 
concentration of inhibition which causes 50% inhibition (IC50) of an enzyme reaction. Biochem. 
Pharmacol. 22: 3099-3108. 
 
De Luca MA, Solinas M, Bimpisidis Z, Goldberg SR, Di Chiara G. Cannabinoid facilitation of 
behavioral and biochemical hedonic taste responses. Neuropharmacology. 2012 Jul;63(1):161-8. 
doi: 10.1016/j.neuropharm.2011.10.018. Epub 2011 Nov 2. PubMed PMID: 22063718; PubMed 
Central PMCID: PMC3705914. 
 
De Luca MA, Valentini V, Bimpisidis Z, Cacciapaglia F, Caboni P, Di Chiara G.  Endocannabinoid 
2-Arachidonoylglycerol Self-Administration by Sprague-Dawley Rats and Stimulation of in vivo 
Dopamine Transmission in the Nucleus Accumbens Shell. Front Psychiatry. 2014 Oct 17;5:140. 
doi: 10.3389/fpsyt.2014.00140. eCollection 2014. PubMed PMID: 25368584; PubMed Central 
PMCID: PMC4201088. 
 
De Luca MA, Bimpisidis Z, Melis M, Marti M, Caboni P, Valentini V, Margiani G, Pintori N, Polis 
I, Marsicano G, Parsons LH, Di Chiara G. Stimulation of in vivo dopamine transmission and 
intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
23 
 
Neuropharmacology. 2015 Oct 6;99:705-714. doi:10.1016/j.neuropharm.2015.08.041. [Epub ahead 
of print] PubMed PMID: 26327678. 
 
Devane, W.A., Dysarz, F.A. 3rd, Johnson, M.R., Melvin, L.S., Howlett, A.C., 1988. Determination 
and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 34 :605-613. 
 
Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, Acquas E, Carboni E, 
Valentini V, Lecca D. Dopamine and drug addiction: the nucleus accumbens shell connection. 
Neuropharmacology. 2004;47 Suppl 1:227-41. Review. PubMed PMID: 15464140. 
 
EMCDDA, European Monitoring Centre for Drugs and Drug Addiction  2009, Understanding the 
‘Spice’ phenomenon, EMCDDA Thematic Paper, Publications Office of the European Union, 
Luxembourg. 
Huffman, J.W., Zengin, G., Wu, M.J., Lu, J., Hynd, G., Bushell, K., Thompson, A.L., Bushell, S., 
Tartal, C., Hurst, D.P., Reggio, P.H., Selley, D.E., Cassidy, M.P., Wiley, J.L., Martin, B.R., 2005. 
Structure–activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and 
CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) 
receptor agonists. Bioorg Med Chem 13: 89 –112.  
Johnston, L.D., O'Malley, P.M., Bachman, J.G. and Schulenberg, J.E., 2013. "Monitoring the 
Future national survey results on drug use, 1975-2012. Volume I: Secondary school students", Ann 
Arbor: Institute for Social Research, The University of Michigan, 604 pp. 
 
Lecca D, Cacciapaglia F, Valentini V, Di Chiara G. Monitoring extracellular dopamine in the rat 
nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
24 
 
self-administration. Psychopharmacology (Berl). 2006 Sep;188(1):63-74. Epub 2006 Jul 19. 
PubMed PMID: 16850116. 
 
Manera, C., Benetti, V., Castelli, M.P., Cavallini, T., Lazzarotti, S., Pibiri, F., Saccomanni, G., 
Tuccinardi, T., Vannacci, A., Martinelli, A., Ferrarini, P.L., 2006.  Design, synthesis, and biological 
evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-
carboxamide derivatives as CB2 selective agonists. J Med Chem. 49: 5947-5957. 
 
Marshell, R., Kearney-Ramos, T., Brents, L.K., Hyatt, W.S., Tai, S., Prather, P.L., Fantegrossi, 
W.E., 2014.  In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and 
phytocannabinoid ∆9-THC in mice: inhalation versus intraperitoneal injection. Pharmacol Biochem 
Behav. 124: 40-7.  
 
Papanti, G.D., Orsolini, L., Francesconi, G., Schifano, F., 2014.  “Noids” in a nutshell: everything 
you (don’t) want to know about synthetic cannabimimetics. Advances in Dual Diagnosis 7: 1-13. 
 
Papanti, D., Schifano, F., Bonavigo, T., Botteon, G., Bertossi, F., Mannix, J., Impagnatiello, M., 
Pascolo-Fabrici, E., 2013 ‘Spiceophrenia’: a systematic overview of ‘Spice’-related 
psychopathological issues and a case report. Human Psychopharmacology: Clinical and 
Experimental. 28: 379-89. 
 
Paxinos, G., & Watson, C. (1998). The rat brain in stereotaxic coordinates, 4th Ed. Academic Press: 
San Diego, CA. 
 
Pertwee, R.G., 2005.  Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 168:1-51. 
Review. PubMed PMID: 16596770. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
25 
 
 
Plymouth Herald, 2015. Available from: http://www.plymouthherald.co.uk 
 
Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially 
increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus 
accumbens. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12304-8.  
 
Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and 
similarity to those of addictive drugs. Nature. 1996 Jul 18;382(6588):255-7. PubMed PMID: 
8717040. 
 
Santacroce, R., Corazza, O., Martinotti, G., Bersani, F.S., Valeriani, G., Di Giannantonio, M., 2015. 
Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently 
harmless products. Hum Psychopharmacol. 30: 265-271. 
 
Schifano, F., Orsolini, L., Papanti, D., Corkery, J., 2015.  Novel psychoactive substances of interest 
for psychiatry. World Psychiatry 14: 15–26.  
 
Simonato,  P.L., Corazza, O., Santonastaso, P., Corkery, J.,  Deluca, P., Davey, Z., Blaszko, U., 
Schifano, F., 2013.  Novel psychoactive substances as a novel challenge for health professionals; 
results from an Italian survey. Human Psychopharmacology: Clinical and Experimental. 28: 324-
331. 
 
Schlatter, J., 2014. Chapter in Studies in Natural Products Chemistry. Edited by Atta-ur- Rahman, 
Elsevier. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
26 
 
 
Spaderna, M., Addy, P.H., D'Souza, D.C., 2013. Spicing things up: synthetic cannabinoids. 
Psychopharmacology (Berl). 228: 525-540.  
 
Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine 
transmission by a common mu1 opioid receptor mechanism. Science. 1997 Jun 27;276(5321):2048-
50. PubMed PMID: 9197269. 
 
Thomas, B.F., Gilliam, A.F., Burch, D.F., Roche, M.J., Seltzman, H.H., 1998. Comparative 
receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther. 285:285-
92. 
 
Uchiyama, N., Kawamura, M., Kikura-Hanajiri, R., Goda, Y., 2012. Identification of two new-type 
synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-
adamantyl)-1-pentyl-1Hindazole-3-carboxamide (APINACA), and detection of five synthetic 
cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs 
in illegal products. Forensic Toxicol 30: 114–125. 
 
Uchiyama , N., Kawamura, M., Kikura-Hanajiri, R., Goda, Y., 2013a. URB-754:a new class of 
designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 227: 21-
32. 
 
Uchiyama, N., Matsuda, S., Kawamura, M., Kikura-Hanajiri, R., Goda, Y., 2013b.Two new-type 
cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic 
carboxamide derivatives, ADBFUBINACA and ADBICA, and five synthetic cannabinoids detected 
with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
27 
 
products. Forensic Toxicol 31: 223–240. 
 
van Amsterdam, J., Brunt, T., van den Brink, W., 2015. The adverse health effects of synthetic 
cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol. 29(3):254-63.  
 
Vigolo, A., Ossato, A., Trapella, C., Vincenzi, F., Rimondo, C., Seri, C., Varani, K., Serpelloni, G. 
Marti, M., 2015. Novel halogenated derivates of JWH-018: behavioral and binding studies in mice. 
Neuropharmacology 95: 68-82.  
 
Wedinos 2014. Philtre issue no. 3. Available from: 
http://www.wedinos.org/resources/downloads/Philtre_Issue_3.pdf (accessed on 3rd August 2015) 
 
Wiley, J. L., Marusich, J. A., Martin, B. R., Huffman, J. W., 2012.  1-Pentyl-3-phenylacetylindoles 
and JWH-018 share in vivo cannabinoid profiles in mice. Drug and Alcohol Dependence, 123: 
148–53. 
 
Zawilska, J.B., Wojcieszak, J.,  2014. Spice/K2 drugs--more than innocent substitutes for  
marijuana. Int J Neuropsychopharmacol. 17(3):509-25.  
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
28 
 
Figures 
 
 
 
 
 
 
 Figure 1 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
29 
 
 
 
Figure 2 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
30 
 
 
 
 
 
 
 
Figure 3 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
31 
 
 
 
 
 
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
32 
 
 
 
Figure 5 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
33 
 
0 60 120
100
125
150
175
Veh
0.03 mg/kg iv
0.1 mg/kg iv
NAc shell
BB-22 0.003 mg/kg iv
0.01 mg/kg iv
*
x
§
§
0 60 120
100
125
150
175 NAc core
BB-22
0 60 120
100
125
150
175 mPFC
BB-22
DA
 
le
ve
ls
 
(%
 
o
f b
as
al
 
va
lu
e)
Time after treatment (min)
 
Figure 6 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
34 
 
 
 
0 60 120 180
100
125
150
175 NAc shell
BB-22 0.01 mg/kg iv AM 251
Veh
* ** *
Time after treatment (min)
D
A
 
le
v
e
ls
 
(%
 
o
f b
a
s
a
l v
a
lu
e
)
 
Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
35 
 
0 60 120 180
100
125
150
175 5F-PB-22
Veh
5F-PB-22 0.01 mg/kg iv
0 60 120 180
100
125
150
175 5F-AKB-48
Veh
5F-AKB-48 0.1 mg/kg iv
*
*
0 60 120 180
100
125
150
175 STS-135
Veh
STS-135 0.15 mg/kg iv
*
DA
 
le
ve
ls
 
(%
 
o
f b
as
al
 
va
lu
e)
Time after treatment (min)
 
 
 
Figure 8 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
36 
 
 
 
Table 1. Binding affinity, potency and efficacy for stimulation of [35S]GTPγS binding in rat 
cortical membranes  
 
 
Data are the means ± SEM of at least four experiments, each performed in triplicate. The 
calculation of IC50 was performed by non-linear curve fitting of the concentration-effect curves 
using Graphpad Prism. IC50 values were converted to Ki values by means of the Cheng and Prusoff 
equation (Cheng and Pursoff, 1973). Compound-mediated  [35S]GTPγS binding data represent 
percentage of stimulation over basal values (set as 100%). Emax and EC50 were determined by non 
linear regression curve fit (GraphPad Prism). One way ANOVA: Ki: F(4,14)=21.24, P<0.0001;  EC50: 
F(4,14) = 14.78 P<0.0001; Emax: F(4,14) =11.56 P< 0.001 P<0.05, P<0.01 and P<0.001 
compared to JWH-018 (Dunnett’s test). 
 
  
CB1 
Ki (nM) 
GTPγS binding  
Compounds EC50  
nM 
Emax 
% over basal 
 
BB-22 
5F-PB-22 
 
0.11± 0.03 
0.13 ± 0.01 
 
2.9 ± 0.6  
3.7 ± 0.6 
 
217 ± 4 
203 ± 2 
5F-AKB48 0.87 ± 0.14 31.0 ± 7.5 190 ± 11 
STS-135 1.93 ± 0.18 32.3 ± 2.9 168 ± 9  
JWH-018 3.38 ± 0.63 20.2 ± 1.3  163 ± 3 
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Supplementary Material 
Characterisation of NPS Internet Products using Nuclear Magnetic Resonance Spectroscopy 
(NMR) 
Nuclear Magnetic resonance spectra were recorded at 289 K using a Jeol Eclipse-400 spectrometer. 
The data is reported as chemical shift (δ) in ppm relative to the residual protonated solvent 
resonance. Relative integral, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), 
coupling constants are reports in Hz. All deuterated solvents were purchased from Sigma Aldrich 
(Gillingham, UK). The number of peaks and splitting patterns are consistent with the chemical 
structures and in line with spectra produced by SWG Drug 1-4. 
5F-AKB-48  
1H-NMR (400 mHz, CDCl3) δ (ppm) 1.45-2.20 (21H, m, alkyl), 4.36-4.37 (1H, m, CH2), 4.47-4.49 
(3H, m alkyl), 6.80 (1H, s, NH), 7.25-7.37 (3H, m, Ar-H), 8.36-8.38 (1H, d, J=8 Hz, Ar-H) 
BB-22 
1H-NMR (400 mHz, CD3OD) δ (ppm) 1.02-1.31 (5H, m, alkyl), 1.62-1.79 (5H, m, alkyl), 1.90-2.03 
(1H, m, CH), 4.12-4.13 (2H, d, J=4 Hz, CH2), 7.22-7.26 (1H, m, Ar-H), 7.28-7.32 (1H, m Hz, Ar-
H), 7.56-7.60 (2H, m, Ar-H), 7.62-7.70 (2H, m,Ar-H), 7.88-7.91 (1H, dd, J=7.6, 1.6 Hz, Ar-H), 
8.11-8.14 (1H, dt, J=8.1 Hz, Ar-H), 8.29 (1H, s, Ar-H), 8.40-8.43 (1H, dd, J=12 Hz, Ar-H), 8.82-
8.85 (1H, dd, J=12 Hz, Ar-H) 
STS-135  
1H-NMR (400 mHz, CD3OD) δ (ppm) 1.35-1.44 (2H, m, CH2), 1.61-1.76 (3H, m, CH2), 1.77 (7H, 
bs, alkyl), 1.85-1.95 (2H, m, CH2), 2.10 (3H, bs, alkyl), 2.20 (7H, m, alkyl),  4.21 (2H, t, J = 6.7 
Hz, CH2), 4.32 (1H, t, J = 8 Hz, CH2), 4.43 (1H, t, J = 8 Hz, CH2), 6.92-6.96 (1H, br, s, NH), 7.11-
7.24 (2H, m, Ar-H), 7.41-7.44 (1H, d, J = 8 Hz, Ar-H), 7.84 (1H, s, CH), 8.00-8.02 (1H, d, J=8 Hz, 
Ar-H) 
5F-PB-22 
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1H-NMR (400 mHz, CDCl3) δ (ppm) 1.47-1.57 (2H, m, CH2), 1.68-1.82 (2H, m, CH2), 1.96-2.09 
(2H, m, CH2), 4.22-4.24 (2H,  , t, J = 8 Hz, CH2),  4.39 (1H, t, CH2), 4.51 (1H, t, CH2)7.27-7.35 
(2H, m, Ar-H), 7.41-7.44 (2H, m, Ar-H),7.54-7.64 (2H, m, Ar-H), 7.75-7.78 (1H, dd, J = 7.9, 1.5 
Hz, Ar-H), 8.17 (1H, s, Ar-H), 8.19-8.24 (1H, dd, J = 8.5, 1.7 Hz, Ar-H), 8.29-8.31 (1H, m,  Ar-H), 
8.90-8.92 (1H, dd, J = 4.1, 1.5 Hz, Ar-H) 
 
References 1-4 
http://www.swgdrug.org/Monographs/5F-AKB48.pdf 
http://www.swgdrug.org/Monographs/5FPB22.pdf 
http://www.swgdrug.org/Monographs/5FPB22.pdf 
http://www.swgdrug.org/Monographs/STS-135.pdf 
 
Characterisation of NPS Internet Products using Gas Chromatography Mass Spectrometry with 
Electron Ionisation (GC-EI-MS). 
HPLC grade methanol was purchased from Fisher Scientific (Loughborough, UK). Samples 
prepared for chromatography analysis were placed in clear DP ID 2 mL glass vials, fitted with 
PTFE/silicone septa certified caps. Analysis was done using electron ionisation (EI) with a scan 
range of 40 - 1000 m/z. Ion trap, manifold and transfer line temperatures were set to 150, 50 and 
250 °C, respectively. Gas chromatographic separation was achieved using a Varian FactorFour 5% 
phenyl-methyl capillary column (30 m x 0.25 mm x 0.25 µm) using helium as a carrier gas (1 ml 
min-1) and a split ratio of 10:1. The column was heated to 50 °C for 2 min following sample 
injection, increased to 300 °C (15 °C min-1), held for 5 min and then cooled back to 50 °C (50 °C 
min-1), with a total run time of 28.67 min. Solutions of each product were prepared of each product 
using methanol (0.1 mg mL-1) and filtered (0.2 µm PTFE membrane filters) prior to analysis. Mass 
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spectra of selected peaks were compared to that of purchased reference standards and the SWG 
Drug Library (Version 2.1). 
The EI fragmentation peaks for the products are reported below as m/z (% abundance) for mass 
peaks ≥ 25% abundance. 
5F-AKB-48 
355 (100), 383 (74), 233 (72), 294 (52), 338 (39), 145 (34), 213 (30), 298 (27), and 356 (25%) 
5F-PB-22 
232 (100), 144 (25), and 116 (25%) 
BB-22 
240 (100) and 144 (31%) 
STS-135 
232 (100), 382 (85), 307 (51), 144 (43), and 365 (32%). 
Characterisation of NPS Internet Products using High Performance Liquid Chromatography 
(HPLC) 
HPLC grade methanol, acetonitrile, water and ortho-phosphoric acid were purchased from Fisher 
Scientific (Loughborough, UK). Reverse phase HPLC analysis was performed using an integrated 
Perkin Elmer Flexar system fitted with an in-line degasser, 100-place auto injector and a photodiode 
array (PDA) detector (recording 210 nm). Data analysis was carried out using Chromera-flexa 
software version 3.4.0.5712. A core kinetix 5µ XB Phenomenex C18 columns (150 x 4.6 mm) was 
used for the analysis. An Isocratic mobile phase was used of 60% orthophosphoric acid (2.1 pH): 
40% AN. The flow rate was 1.5 mL min-1 with an injection volume of 5 µL. Stock solutions of each 
NPS were prepared by adding 5.0 mg of each component weighed accurately into 10 mL 
volumetric flasks and made up to volume with methanol. Each NPS sample was prepared and 
analysed in triplicate. A calibration curve was constructed using the following standards: 1, 0.66, 
0.44, 0.29, 0.19, and 0.13 mg ml-1.   
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HPLC was used to run the reference standards 5F-AKB-48 (RT = 16.3 min), 5F-PB-22 (RT =3.4 
min), BB-22 (RT = 8.9 min), STS-135 (RT = 9.2 min) and evaluate the purity of the Internet 
products. Correlation coefficients for all calibration curves were ≥0.999. The purity of the 5F-AKB-
48, 5F-PB-22, BB-22, and STS-135 Internet products were determined to be 93 ± 1% (RT = 16.2 
min), 95.2 ± 0.8% (RT = 3.4 min), 90.6 ± 0.6% (RT = 8.9 min), and 91 ± 2% (RT = 9.2 min), 
respectively. 
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HIGHLIGHTS 
• STS-135, 5F-AKB-48, BB-22, 5F-PB-22 are 3rd generation Spice/K2 synthetic 
cannabinoids 
• They are CB1 receptor ligands with higher affinity than JWH-018 
• They are CB1 agonists with higher potency and intrinsic activity than JWH-018 
• They increase NAc shell dopamine at doses consistent with their in vitro potency 
 
 
 
 
 
 
 
